Chronic rhinosinusitis (CRS) is an inflammatory disease of the nose and paranasal sinuses commonly divided into a form with nasal polyps (CRSwNP) and a form without nasal polyps (CRSsNP). There is a particularly severe form of CRSwNP in which subjects have comorbid asthma and sensitivity to aspirin and other COX1-inhibiting drugs referred to as aspirinexacerbated respiratory disease (AERD). However, there is still an ongoing debate about the underlying pathological mechanisms of this phenotype of disease. Distinguishing subjects with AERD from subjects with CRSwNP is important because asthma exacerbations secondary to aspirin sensitivity have high This study was supported in part by the Chronic Rhinosinusitis Integrative Studiesmorbidity in AERD and because the pathophysiology of these 2 phenotypes appears to be distinct. 1, 2 Diagnosis based on patients' recall of a history of aspirin sensitivity is not always reliable. It was reported that 15% to 34% of subjects with rhinosinusitis with asthma were unaware of their aspirin intolerance until they developed symptoms during a monitored aspirin challenge, and up to 15% of subjects with asthma who reported a history of aspirin intolerance had negative aspirin challenge test results. 1, 3, 4 However, aspirin challenges to diagnose AERD are not routinely performed in a clinical setting given the length of time needed to perform the challenge and the potential risk of inducing a severe reaction. New biomarkers are needed to clarify the diagnosis and pathophysiology of CRSsNP, CRSwNP, and AERD, especially to objectively distinguish AERD from CRSwNP.
Microparticles (MPs) are extracellular vesicles ranging in size from 100 to 1000 nm that are released by shedding from the plasma membrane of various cell types, especially when they are activated or undergo apoptosis in response to injury. 5 Growing evidence has suggested that the levels and markers of released MPs are biomarkers of the degree of injury, activation, and apoptosis of cells from which they are derived in various diseases. For example, endothelial MPs are increased in subjects with disorders such as cardiovascular diseases, [6] [7] [8] renal failure, 9 metabolic diseases, 10 and chronic obstructive pulmonary disease 11 in response to endothelial injury. The release of E-selectin endothelial MPs is an indicator of endothelial activation, whereas Annexin V positive platelet endothelial cell adhesion molecule-1 (PECAM) positive endothelial MPs have been used as an indicator of endothelial apoptosis. 12, 13 MPs are distinct from exosomes, which are smaller extracellular vesicles released from cells through exocytosis of multivesicular bodies. 5 In the case of MPs, the markers expressed on the cell of origin are expressed on the membrane of the MPs because they are formed by blebbing of plasma membrane. Thus, MP analysis can be used to evaluate the type of cells that are injured and the state of activation or apoptosis of injured cells. Assay of MPs has been shown to have significant value in quantifying the degree of cell injury and activation in clinical samples. 8, 14 We report here the successful use of MP assessment of nasal lavage fluids (NLFs) to evaluate the pathophysiology of CRS using flow cytometry with a standardized MP gating strategy. 15, 16 Disruption of the epithelial barrier has been speculated to initiate chronic inflammation in CRS. [17] [18] [19] Eosinophils and mast cells have been reported to be involved in the pathophysiology of CRS. 20, 21 Elevated basophil counts were reported in polyps of subjects with CRSwNP. 22 Abnormal platelet activation was reported in AERD. 23, 24 Our present study demonstrates that measuring MPs in NLFs may be an effective tool to study the pathogenesis of CRS, showing consistency with many of these previously published findings. Furthermore, we demonstrate that some MP types have potential use as biomarkers that distinguish subjects with AERD from subjects with CRSwNP independently of comorbid asthma and ongoing steroid use.
METHODS

Patient population
See this article's Online Repository at www.jacionline.org.
NLF sampling and processing
Measurement of MPs in nasal lavage by flow cytometry
MPs in NLFs were measured by flow cytometry as previously described.
11 NLF samples were incubated with each specific antibody (see Table E1 in this article's Online Repository at www.jacionline.org) and were analyzed using a BD FACS LSRII flow cytometer and BD FACS DIVA software version 8.0 (BD Biosciences, Erembodegem, Belgium). The MP gate was determined using Megamix plus SSC beads (BioCytex, Marseille, France) with a standardized MP gating strategy 15, 16 (see Fig E1 in this article's Online Repository at www.jacionline.org). The gating strategies of previously unstudied MP types were verified using positive control MPs isolated from culture supernatant of each cell type or plasma (see Fig E8 in this article's Online Repository at www.jacionline. org). MP levels were evaluated as absolute MP numbers per 1 mL of NLF (/mL NLF) using flowcount beads. Preliminary experiments showed that our MP assay has good repeatability (see Fig E7 in this article's Online Repository at www.jacionline.org). Further details are provided in this article's Online Repository at www.jacionline.org.
Characterization of MPs
We quantified MPs from 7 different cell types, including some previously unstudied MP types (epithelial MPs, eosinophil MPs, mast cell MPs, and basophil MPs), with activation or apoptosis markers, for a total of 16 different data sets as shown in Table I . MPs were defined as particles that ranged from 0.1 to 1.0 mm in size and were positively labeled with specific antibodies. Epithelial MPs (E-cadherin(1)MPs: E-cad1EpiMPs, epithelial cell adhesion molecule [EpCAM] (1)MPs: EpCAM1EpiMPs), eosinophil MPs (EGF-like modulecontaining mucin-like hormone receptor-like 1[EMR1](1)MPs: EoMPs), mast cell MPs (high-affinity IgE receptor [FcεRI] (1)c-kit(1)MPs: MCMPs), and basophil MPs (CD203c(1)c-kit(2)MPs: BasoMPs) are abbreviated as shown and were defined using cell-specific markers as indicated and previously reported. [25] [26] [27] [28] [29] [30] Activated eosinophil MPs (CD69(1)EoMPs: ActEoMPs) and activated mast cell MPs (CD137(1)MCMPs: ActMCMPs) were defined as previously reported. [31] [32] [33] [34] [35] [36] [37] Basophil activation was evaluated using mean fluorescence intensity of CD203c on basophil MPs. We did not use CD63, another basophil activation marker, because platelets express CD63 and adhere to leukocytes in subjects with AERD. 38 Apoptotic eosinophil MPs (Annexin V(1) EoMPs: ApoEoMPs), apoptotic basophil MPs (Annexin V(1)BasoMPs: ApoBasoMPs), and apoptotic or degranulated mast cell MPs (Annexin V(1) MCMPs: AV1MCMPs) were defined using Annexin V. Further details are provided in this article's Online Repository at www.jacionline.org.
Statistics
All data were analyzed using nonparametric methods unless stated otherwise. A P value of less than .05 was considered significant. Further details are provided in this article's Online Repository at www.jacionline.org.
RESULTS
Subjects' demographic characteristics
The demographic characteristics of the subjects in this study are presented in Table II . There were no significant differences in age, sex, ethnicity, atopy, or past smoking status among the groups. In addition, there were no significant differences in the distribution of comorbid atopy among subjects with CRSsNP, CRSwNP, and AERD. The proportion of comorbid asthma was significantly higher in subjects with CRSwNP than in subjects with CRSsNP (P < .03), and was significantly higher in subjects with AERD than in subjects with CRSsNP (P < .0001) or subjects with CRSwNP (P <.0001). Furthermore, when compared with subjects with CRSsNP, the proportion of oral steroid use was significantly higher in subjects with AERD than in subjects with CRSsNP (P < .002) or CRSwNP (P < .05), but there was no significant difference in the prevalence of intranasal steroid use.
Comparisons of endothelial MP and epithelial MP levels in NLFs
EndoMPs (PECAM endothelial MPs) were measured as a marker for endothelial injury. 8, 9 ActEndoMPs (E-selectin endothelial MPs) were measured as a marker for endothelial activation. 7, 11, 12, 39, 40 Compared with control, ActEndoMPs were significantly increased in subjects with CRSsNP (1.8-fold vs control median, P < .02), CRSwNP (1.7-fold, P < .03), and AERD (3.2-fold, P <.0001) (Fig 1, A) . EndoMPs were also significantly increased in subjects with CRSsNP (1.7-fold, P < .002), CRSwNP (1.4-fold, P < .03), and AERD (1.6-fold, P < .0005) (Fig 1, B) . EpCAM is located on the basolateral side of epithelial cells, whereas E-cadherin is localized in adherens junctions. 41 Loss of intercellular junctions and cellular detachment from basement membranes are observed during epithelial injury. 42, 43 We measured both EpCAM1EpiMPs and E-cad1EpiMPs to evaluate degrees and conditions of epithelial injury. Compared with control, EpCAM1EpiMPs were significantly increased in subjects with CRSsNP (1.6-fold, P < .05) and AERD (2.4 fold, P < .001) (Fig 1, C) but were not increased in subjects with CRSwNP (P 5.91). Levels in subjects with CRSwNP were lower than in subjects with CRSsNP (P < .02) and AERD (P < .0003). E-cad1EpiMPs were significantly increased in subjects with CRSsNP (2.9-fold, P < .0003), CRSwNP (1.5-fold, P < .05), and AERD (2.3-fold, P < .0001) (Fig 1, D) . Similarly, E-cad1EpiMPs in subjects with CRSwNP were significantly lower than in subjects with CRSsNP (P < .004) and AERD (P < .002).
Comparisons of platelet MP levels in NLFs
Platelet MPs (PltMPs) are released from activated platelets, associated with phosphatidylserine externalization, and regarded as markers for platelet activation. [44] [45] [46] Compared with control, PltMPs were significantly increased only in subjects with AERD (3.5-fold, P < .0003) (Fig 1, E) .
Comparisons of eosinophil MP, mast cell MP, and basophil MP levels in NLFs
When compared with control, EoMPs were significantly increased in subjects with CRSsNP (1.8-fold, P < .0001), CRSwNP (1.6-fold, P < .0001), and AERD (1.9-fold, P < .0001) (Fig 1, F) . ActEoMPs were also significantly increased in subjects with CRSsNP (2.2-fold, P <.01), CRSwNP (2.3-fold, P <.03), and AERD (3.1-fold, P < .001) (Fig 1, G) . ApoEoMPs were significantly increased in subjects with CRSsNP (1.6-fold, P < .0001), CRSwNP (2.2-fold, P < .0001), and AERD (2.4-fold, P <.0001) (Fig 1, H) . Compared with controls, MCMPs were significantly increased only in subjects with AERD (4.3-fold, P < .002) and were not increased in subjects with CRSsNP or subjects with CRSwNP (Fig 1, I ). In contrast, ActMCMPs were significantly increased in subjects with CRSsNP (2.4-fold, P < .03), CRSwNP (2.4-fold, P < .02), and AERD (7.4-fold, P < .0002) (Fig 1, J) . AV1MCMPs were significantly increased only in subjects with AERD (4.9-fold, P < .0003) (Fig 1, K) . When compared with control, BasoMPs were significantly increased only in subjects with AERD (2.5-fold, P < .05) (Fig 1, L) . However, the mean fluorescence intensity of CD203c on BasoMPs was increased in both subjects with CRSwNP (P < .002) and subjects with AERD (P < .0001) (Fig 2) . ApoBasoMPs were increased only in subjects with AERD (2.3-fold, P < .006) and were not increased in either subjects with CRSsNP or subjects with CRSwNP (Fig 1, M) .
Comparisons of Annexin V positive MP, erythrocyte MP, and membrane dye positive MP levels in NLFs
When compared with control, the total level of Annexin V positive MPs, regardless of cell type of origin, was significantly increased in subjects with CRSwNP (1.4-fold, P < .02) and AERD (1.4-fold, P < .02) but not in subjects with CRSsNP (see Fig E2, A, in this article's Online Repository at www.jacionline.org). When compared with control, erythrocyte MPs were not increased in subjects with CRSsNP, CRSwNP, or AERD (Fig E2, B) . To observe the trends of total MP levels in NLFs, we measured membrane dye positive MPs (lipid-FM specific dye [FM] (1)carboxyfluorescein succinimidyl ester [CFSE] (1)MPs) as previously described. 47 When compared with control, FM1CFSE1MP levels were significantly increased in subjects with CRSsNP (1.6-fold, P < .0007), CRSwNP (1.3-fold, P < .003), and AERD (2.0-fold, P < .0001). In addition, FM1CFSE1MP levels were higher in subjects with AERD than in subjects with CRSsNP (P < .005) and CRSwNP (P < .0003) (Fig E2, C) .
Receiver operating characteristic curve analysis of MP levels for distinguishing AERD from CRSwNP
We assessed the feasibility of using levels of MPs as biomarkers to distinguish subjects with AERD from subjects with CRSwNP (45 subjects with CRSwNP and 31 subjects with AERD) using area under the curve (AUC) analysis. There were significant differences in levels of ActEndoMPs, PltMPs, EpCAM1EpiMPs, E-cad1EpiMPs, MCMPs, ActMCMPs, AV1MCMPs, BasoMPs, and ApoBasoMPs between subjects with CRSwNP and subjects with AERD. The results of this analysis are summarized in Table III . There were significant differences in the distribution of oral corticosteroid use and asthma between the 2 groups. The multivariate logistic analysis showed that the following MP types had cutoff values that were significantly associated with AERD, independent of asthma and oral steroid use (see Table E2 in this article's Online Repository at www.jacionline.org): cutoff values of PltMPs, 206/mL (AUC, 0.77; sensitivity, 68%; specificity, 84%) (Fig 3, A) ; EpCAM1EpiMPs, 3687/mL (AUC, 0.75; sensitivity, 52%; specificity, 91%) (Fig 3, B) ; E-cad1EpiMPs, 1027/mL (AUC, 0.72; sensitivity, 74%; specificity, 64%) (Fig 3, C) ; MCMPs, 854/mL (AUC, 0.70; sensitivity, 74%; specificity, 64%); ActMCMPs, 424/mL (AUC, 0.71; sensitivity, 58%, specificity, 80%); AV1MCMPs, 192/mL (AUC, 0.72; sensitivity, 81%; specificity, 60%) (Fig 3, D) ; and ApoBasoMPs, 0.69/mL (AUC, 0.69; sensitivity, 61%; specificity, 73%).
Comparisons of MP levels between subjects with CRSwNP without asthma and subjects with CRSwNP with aspirin-tolerant asthma, and comparison between subjects with CRSwNP with aspirin-tolerant asthma and subjects with AERD Although the proportion of females was significantly higher in subjects with CRSwNP without asthma than in subjects with CRSwNP with aspirin-tolerant asthma (ATA) (P < .03), there was no significant difference in the other patient demographic end points between these 2 groups (see Table E5 in this article's Online Repository at www.jacionline.org). There was no significant difference in levels of any MP types between subjects with CRSwNP without asthma and subjects with CRSwNP with ATA (see Table E6 in this article's Online Repository at www.jacionline.org). There was no difference in the patient demographic end points between subjects with CRSwNP with ATA and subjects with AERD. Even when compared with the more narrowly defined group of subjects with CRSwNP with ATA, levels of PltMPs (P < .0003), EpCAM1EpiMPs (P < .0005), E-cad1EpiMPs (P < .02), MCMPs (P < .02), ActMCMPs (P < .02), AV1MCMPs (P < .02), and ApoBasoMPs (P < .006) were still higher in subjects with AERD. There was no significant difference in levels of the other MP types between these 2 groups (ActEndoMPs: P 5 .061, EndoMPs: P 5 .588, EoMPs: P 5 .386, ActEoMPs: P 5 .241, ApoEoMPs: P 5 .698, BasoMPs: P 5 .165, and mean fluorescence intensity of CD203c on BasoMPs: P 5 .116).
DISCUSSION
This is the first study to evaluate the pathophysiology of CRS and AERD by analyzing released MP levels and types in NLFs. The findings are summarized in Table IV and Fig 4 . MPs were detected in NLFs of both controls and subjects with CRS, and there were similarities as well as significant differences in MP types and levels comparing NLFs from subjects with CRSsNP, CRSwNP, and AERD. MPs contain various bioactive effectors originating from the parent cells that can actively modulate immune responses under both normal healthy and pathological conditions. 5, 48, 49 Our results indicate that MPs were released from activated immune cells and injured structural cells into the nasal cavity under pathological and healthy normal conditions and may play roles in cell-to-cell communication in the nose and paranasal sinuses. Furthermore, we demonstrate that several MP types have potential use as biomarkers to distinguish subjects with AERD from subjects with CRSwNP independently of asthma and steroid intake, especially PltMPs (AUC, 0.77; sensitivity, 68%; specificity, 84%), EpCAM1EpiMPs (AUC, 0.75; sensitivity, 52%; specificity, 91%), and AV1MCMPs (AUC, 0.72; sensitivity, 81%; specificity, 60%). Current estimates of AERD prevalence among patients with CRS and among the general population are variable because of variations in diagnostic methods and definitions. 1 In this study, aspirin intolerance was diagnosed on the basis of clinical history (reports from patients and/or in patient charts). However, clinical history alone may not be sufficient to diagnose all subjects with AERD. 50 As such, oral aspirin challenges remain the criterion standard for confirming this disease.
1,3,4 Future analysis of MPs in a large cohort of subjects with challenge-confirmed AERD is essential to establish the usefulness of MP levels in NLFs as biomarkers.
If validated in such a study, the use of MP may help to better estimate AERD prevalence and help standardize the diagnosis of AERD. Convincing evidence implicates epithelial barrier disruption in the pathogenesis of asthma, eczema, and CRS. 19, 51 However, there have been no reports evaluating the degree of epithelial injury in CRS and comparing subjects with CRSsNP, CRSwNP, and AERD. In this study, both EpCAM1EpiMPs and E-cad1EpiMPs were significantly increased in subjects with CRSsNP and subjects with AERD when compared with control subjects (Fig 1, C and D) . E-cadherin is localized only in adherens junctions. 41 Thus, the increased E-cad1EpiMPs in the nasal cavity may reflect a loss of intercellular adherens junctions in subjects with CRSsNP and subjects with AERD as observed during epithelial injury. 43 In contrast, EpCAM is located on the basolateral side. 41 The increased EpCAM1EpiMPs may reflect detachment of epithelial cells from basement membranes in subjects with CRSsNP and subjects with AERD as observed during epithelial injury. 42 Our results indicate that epithelial barrier disruptions are induced by loss of both intercellular junctions and cellular attachment to the basement membrane in subjects with CRSsNP and subjects with AERD. However, EpCAM1EpiMPs and E-cad1EpiMPs were both significantly lower in subjects with CRSwNP when compared with subjects with CRSsNP or AERD, indicating a lower degree of epithelial injury in subjects with CRSwNP than in subjects with CRSsNP or AERD. Interestingly, although E-cad1EpiMPs were significantly increased, EpCAM1EpiMPs were not increased in subjects with CRSwNP. Epithelial barrier disruption may be induced mainly by loss of intercellular junctions in subjects with CRSwNP. Variable epithelial barrier disruption may reflect heterogeneity of inflammatory mechanisms and histological changes among subjects with CRSwNP, subjects with CRSsNP, and subjects with AERD.
The accumulation of eosinophils in polyps has been known for over a century. 22, 52, 53 In our studies, eosinophil cationic protein (ECP) levels in NLFs were significantly increased in subjects with CRSwNP and subjects with AERD when compared with subjects with CRSsNP (see Fig E5 in this article' s Online Repository at www.jacionline.org), indicating that a high degree of eosinophil degranulation occurs in subjects with CRSwNP and subjects with AERD, but not in subjects with CRSsNP. However, we were surprised to find that there was no significant difference in EoMP and ActEoMP levels among subjects with CRSsNP, subjects with CRSwNP, and subjects with AERD (Fig 1, F and G) . Because eosinophils accumulate in most polyps, our results may indicate that the number of released EoMPs and ActEoMPs per eosinophil was higher in subjects with CRSsNP, suggesting that the degree of activation per eosinophil was higher in nonpolypoid diseases than in polypoid disease. Eosinophils may also be activated in nonpolypoid diseases without eosinophil accumulation and degranulation. Although correlations between ActEoMPs and ECP levels were weak (CRSwNP: r s 5 0.358, P < .04; AERD: r s 5 0.111, P 5 .63), a recent article reported relationships between exosome release and eosinophil degranulation. 54 Exosomes in eosinophils contain eosinophil peroxidase (EPO), major basic protein (MBP), and ECP, and are secreted after induction of degranulation in vitro. 54 In contrast with MP release, exosome secretion can occur both spontaneously and BasoMPs among subjects with CRSsNP, subjects with CRSwNP, subjects with AERD, and control subjects. **P < .01 and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 3 constitutively, and is controlled in different cell types by various environmental influences. 5, 54 Eosinophil degranulation may be a specific feature of eosinophil activation under the microenvironment of polyps. Analysis of extracellular vesicles may improve our understandings and quantification of eosinophil activation in CRS. (19, 955) All data of MP levels are presented as median (range). ##-fold, significantly higher by ##-fold vs control. Increased, significantly higher in MFI vs control. MFI, Mean fluorescence intensity; NS, not significant vs control.
Tryptase-positive mast cells are increased in CRS, along with increased IgE levels in many cases, and have been implicated in pathogenesis. 21, 55 ActMCMPs were increased 2-fold in subjects with CRSsNP and subjects with CRSwNP, and increased an impressive 7.4-fold in subjects with AERD when compared with control subjects (Fig 1, J) . In addition, ActMCMPs showed strong correlations with ActEoMPs (see Fig E4 in this article' s Online Repository at www.jacionline.org). These results indicate that mast cells are profoundly activated in subjects with AERD, more so than in subjects with CRSsNP and subjects with CRSwNP. Furthermore, the correlations of ActMCMPs with ActEoMPs suggest that the activation pathways for these 2 cells may be similar, or related. Interestingly, AV1MCMPs were significantly increased (4.9-fold) only in subjects with AERD and were not increased in subjects with CRSsNP or CRSwNP. Because phosphatidylserine externalization occurs in the process of mast cell degranulation, 56 our results may indicate that mast cell activation, rather than apoptosis, is what we are detecting with this MP analysis. There was no significant difference in mast cell MP levels between subjects with AERD with and without atopy (data not shown). Non-IgE-dependent mast cell activation was also reported to play an important role in the pathophysiology of AERD. 57 However, there are no established mast cell activation cell surface markers specific for IgE-independent pathways. Discovery of markers unique to non-IgE-dependent mast cell activation and evaluation of non-IgE pathway activation using MP assays could be useful in future studies.
In this study, MP findings indicate that basophils are not activated in subjects with CRSsNP, but are activated in subjects with CRSwNP and subjects with AERD (Fig 2) . This may be in concordance with the type 2 cytokine pattern in subjects with CRSwNP and subjects with AERD. In addition, ApoBasoMPs were significantly increased only in subjects with AERD but not in any other subject group (Fig 1, M) , indicating that apoptosis is induced in basophils only in subjects with AERD. Furthermore, BasoMP levels in subjects with AERD were higher than in subjects with CRSwNP (Fig 1, L) , indicating that the degree of basophil activation is likely higher in subjects with AERD than in subjects with CRSwNP. In a recent study, we reported lower basophil counts in polyps in subjects with AERD compared with subjects with CRSwNP and speculated that the basophils are likely migrating to AERD polyps and then become undetectable because of either degranulation or apoptosis. 22 The finding in the present study suggests that the highest level of activation and apoptosis in basophils occurs in AERD polyps, supporting this previous speculation.
PltMPs were significantly increased only in subjects with AERD, and not in the other phenotypes of CRS in this study (Fig 1, E) . In addition, PltMPs were strongly correlated with ActEoMPs in subjects with AERD (see Table E3 and Fig E3 in this article's Online Repository at www.jacionline.org). Platelet MPs have previously been reported to be shed from activated platelets and are regarded as both effectors and biomarkers for platelet activation. 44, 45 Our results provide further support to the concept that platelets are activated in subjects with AERD, even without treatment with COX1 inhibitor drugs. Laidlaw et al 38 reported that platelets adhere to eosinophils and neutrophils and can be found within nasal polyp tissue in subjects with AERD to a greater extent than in subjects with CRSwNP. 38 The present studies support their conclusion, and suggest that the high degree of platelet activation is unique to AERD among the types of CRS that we studied here. The use of MPs to assess the level of activation of platelets within NLF may provide an important new tool to study disease prevalence, progression, and remission in AERD.
It should be noted that there are some interesting patterns of baseline MP levels in NLFs of control subjects. Although platelet MPs and endothelial MPs are the major populations of MPs in the J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 3 plasma, 58, 59 baseline PltMP levels were very low in NLFs (about 4% of EndoMP). In addition, although basophils are rare populations in both the nasal cavity and blood, baseline BasoMP levels were the highest (as high as EndoMPs) among the MP types in NLFs. We also measured baseline BasoMPs and EndoMPs in the plasma (n 5 9), and found that baseline BasoMP levels were around 40% of the level of EndoMPs (see Table E4 in this article's Online Repository at www.jacionline.org). MP levels in NLFs and plasma reflect the balance between MPs that are released from the cells of origin and MPs that are taken up by target cells. We speculate that this balance may be different between the nasal cavity and the circulation, or among MP types. Differences in the rate of turnover among the cell types may also influence baseline levels of each MP type. Mechanisms of MP release and uptake in in vivo models have not been clarified yet and should require further study.
There are a number of limitations of this study. Although there was no difference in the prevalence of nasal steroid use among subjects with CRSsNP, subjects with CRSwNP, and subjects with AERD, the number of subjects using oral corticosteroids in AERD was significantly higher than in the other forms of CRS. Glucocorticoids can induce apoptosis in immune cells such as eosinophils, 60 and basophils. 61 However, there was no significant difference in levels of any MP types between subjects with AERD with and without oral steroid use in this study (data not shown). The increased ApoEoMPs and ApoBasoMPs may be specific features of AERD. In addition, platelet MPs in plasma were reported to be significantly increased in subjects with asthma, which is one of the triad of conditions defining AERD. 62 Although growing evidence has suggested that abnormal platelet activation is uniquely associated with the pathophysiology of AERD independently of asthma, 23, 24 further studies are necessary to clarify this point. However, PltMP levels in NLFs were higher in subjects with AERD than in subjects with CRSwNP with ATA, and the multivariate logistic analysis showed that our cutoff values of platelet MPs, EpiMPs, and MCMPs were significantly associated with AERD independently of asthma in this study. Furthermore, MP assay in NLFs is representative of inflammation in the entire nasal cavity and NLFs have not yet been isolated from specific anatomic structures within the nose and sinuses. Thus, it is impossible to clarify the parts of the nasal cavity from which MPs in NLF are originating. To address this weakness, we are now developing a new assay using a sponge-based approach 63 to collect MPs released from specific anatomic structures in nasal cavity.
In conclusion, we found evidence for activation of endothelium, epithelium, mast cells, basophils, eosinophils, and platelets in the various forms of CRS and also found clear differences among the phenotypes of disease. Furthermore, we found that some MP types, especially EpCAM1EpiMPs, PltMPs, and AV1MCMPs, are potential biomarkers for distinguishing AERD from CRSwNP in the clinic. Although platelet activation markers were reported to be potential diagnostic biomarkers for AERD in blood, 23 MP analysis in NLF may make diagnosis of AERD more robust by evaluating both EpiMPs and AV1MCMPs in addition to PltMPs. Recently, group 2 innate lymphoid cells (ILC2) have been detected in nasal polyp tissues and interest has focused on their role in the pathophysiology of CRS. 64, 65 At present, definitively detecting ILC2 requires a cocktail of several cell surface markers, making detection of ILC2-derived MP challenging. Developing reliable MP analysis of these cells is of great interest to us. We measured NLF samples collected from patients taken in the operating room in this study. However, in results not shown, we have recently found that MPs were also detectable in NLFs collected from patients during a routine clinical office visit. We believe that MPs in NLFs may become an invaluable tool in the study of CRS and AERD in the laboratory and provide new biomarkers for the diagnosis and treatment of CRS in the clinic.
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Key messages
d MPs may be useful to assess the degree of cell injury, activation, and apoptosis relevant to the pathophysiology of CRS and AERD.
d Analysis of MP subsets suggests that mast cells, platelets, basophils, and endothelial cells are all more highly activated in AERD than in CRS.
d Platelet MPs, EpiMPs, and MCMPs may have utility as biomarkers to distinguish AERD from CRSwNP in both clinical and research settings.
